ABOUT THE STUDY:

Asthma is one of the most common chronic diseases in children and treatment success often depends on proper inhaler use and consistent medication adherence. Exposure to allergens and pollutants may also impact treatment response and asthma control. Moreover, there is a growing need for non‑invasive biomarkers to support better diagnosis and personalized care.

The Care4Asthma study combines the use of a digital inhaler that monitors medication administration, exposure assessment and biomarker research. The study aims to optimize and personalize medical care for children living with asthma.

1. Recruitment of children aged 5 to 16 years with partly controlled or uncontrolled asthma requiring treatment with inhaled corticosteroids (Centre Hospitalier du Luxembourg, KannerKlinik)

2. Comparison of inhaled corticosteroid treatment adherence and asthma control between children using a new digital inhaler (Whizz spacer, Meracle Health) and those using a standard, non-digital inhaler (AeroChamber Plus® Flow-Vu®).

3. Identification of biomarkers and immune signatures related to asthma diagnosis, treatment response and risk of asthma exacerbation.

4. Assessment of environmental exposure to allergens and to organic pollutants to evaluate the association with asthma control.

WHY DOES THE CLINICAL STUDY MATTER:

The Care4Asthma study will help in advancing the diagnosis and treatment of pediatric asthma and in supporting research that aims to answer important questions, including:

• Does the use of digital inhalers improve adherence to inhaled corticosteroids and asthma control in children?
• Which biomarkers could support diagnosis and help predict treatment responses in children with asthma?
• Can specific immune signatures serve as new therapeutic targets?
• How do environmental factors influence asthma control and treatment outcomes?

The insights obtained from this pediatric cohort study will contribute to improving treatment strategies and enhancing the quality of life for children living with asthma.